Tyra Biosciences (TYRA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Tyra Biosciences (TYRA) is a US-listed Healthcare company in Biotechnology with a market capitalization of
1.31 on the NASDAQ. This SniperIQ fundamentals page covers Tyra Biosciences's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tyra Biosciences's market cap?
Tyra Biosciences (TYRA) has a market capitalization of approximately
1.31 on the NASDAQ. Market cap moves with the live share price.What is Tyra Biosciences's P/E ratio?
Tyra Biosciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tyra Biosciences?
Tyra Biosciences runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Tyra Biosciences pay a dividend?
Tyra Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Tyra Biosciences financially healthy?
Tyra Biosciences carries a debt-to-equity ratio of 0.01x and a current ratio of 20.49x, with a market beta of 0.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tyra Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tyra Biosciences (TYRA) the key facts are: market cap
Track Tyra Biosciences's full fundamentals live
Get Tyra Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.